BOULDER, Colo.--(BUSINESS WIRE)--PanTheryx®, a global nutrition and biotechnology company, today announced the launch of Relesium™, a patented, all-natural supplement formulated to address pervasive gut-related side effects of glucagon-like peptide 1 (GLP-1) medications, including popular weight-loss drugs like Ozempic®, Wegovy®, Mounjaro® and other Semaglutides and Tirzepatides.

科罗拉多州博尔德（商业新闻短讯）--全球营养和生物技术公司PanTheryx®今天宣布推出Relesium™，这是一种获得专利的全天然补充剂，旨在解决胰高血糖素样肽1（GLP-1）药物的普遍肠道相关副作用，包括流行的减肥药物，如Ozempic®、Wegovy®、Mounjaro®和其他Semaglutides和Tirzepatides。

Relesium combines the scientifically backed benefits of chicken egg powder and bovine colostrum, offering an all-natural solution for companies aiming to address digestive discomfort, such as nausea, acid reflux, bloating, constipation, and diarrhea, experienced by a substantial portion of GLP-1 users worldwide..

。。

With rising GLP-1 use for weight loss, diabetes and other health conditions, one in eight Americans now rely on these drugs, with up to 50% of GLP-1 patients reporting mild to moderate gastrointestinal side effects. This leads many to reduced dosages of the drugs and up to 30% of users to discontinue the treatment, despite the tremendous health benefits.

随着用于减肥、糖尿病和其他健康状况的GLP-1使用量的增加，八分之一的美国人现在依赖这些药物，高达50%的GLP-1患者报告轻度至中度胃肠道副作用。这导致许多人减少了药物的剂量，尽管有巨大的健康益处，但多达30%的使用者停止了治疗。

While current recommendations focus on diet modification, such as consuming small, bland meals, many patients seek additional support to manage symptoms effectively without turning to other medications that may interfere with the GLP-1 efficacy..

虽然目前的建议侧重于饮食调整，例如食用少量平淡的食物，但许多患者寻求额外的支持，以有效控制症状，而无需转向其他可能干扰GLP-1疗效的药物。。

PanTheryx, the developer of Relesium, is committed to making this gut-health solution widely accessible. “Relesium is entering a largely untapped market addressing a need for an all-natural, fast-acting and patented solution to alleviate the GI discomfort millions worldwide experience with GLP-1 drugs, while also helping to restore the gut microbiome,” said Tom Feeley, CEO of PanTheryx.

Relesium的开发者PanTheryx致力于使这种肠道健康解决方案广为使用。。

“This ingredient now allows health and wellness companies to offer their customers a science-backed product that addresses these challenges without compromising the effectiveness of their GLP-1 therapy and additional medications.”.

“这种成分现在使健康和保健公司能够为客户提供一种科学支持的产品，以应对这些挑战，而不会损害其GLP-1疗法和其他药物的有效性。”。

Evidence-based Insights and Promising Findings

基于证据的见解和有希望的发现

A new publication in Nutrients, a leading peer-reviewed journal on human nutrition, has highlighted the potential of Relesium for gut health and GLP-1 patients. Raymond Playford, M.D., PhD, a gastroenterologist and long-standing scientific advisor for PanTheryx, and Professor of Molecular Medicine at the University of West London, authored the article that consolidates the growing body of research on chicken egg powder and bovine colostrum.

。医学博士雷蒙德·普莱福德（RaymondPlayford）是一位胃肠病学家，也是PanTheryx的长期科学顾问，也是西伦敦大学的分子医学教授，他撰写了这篇文章，巩固了越来越多的鸡蛋粉和牛初乳研究。

According to Dr. Playford’s analysis, both ingredients offer significant gut-stabilizing benefits, particularly when used in combination due to their synergistic effects..

根据Playford博士的分析，这两种成分都具有显着的肠道稳定作用，特别是由于它们的协同作用而联合使用时。。

Dr. Playford explains that “the combination of egg and bovine colostrum not only supports gut stability but also delivers high-quality protein and essential micronutrients—vitamins, minerals, and antioxidants—particularly important for GLP-1 users who may experience reduced appetite, fatigue, and significant energy loss.

Playford博士解释说，“鸡蛋和牛初乳的结合不仅支持肠道稳定性，而且还提供高质量的蛋白质和必需的微量营养素维生素，矿物质和抗氧化剂，对于可能经历食欲下降，疲劳和显着能量损失的GLP-1使用者来说尤为重要。

It also contains prebiotics, to support a healthy microbiome and several other factors such as immunoglobulins and antimicrobial peptides, that help prevent adhesion of microbes to gut surfaces, inhibit bacterial metabolism, and neutralize toxins and viruses.”.

它还含有益生元，以支持健康的微生物组和其他几种因素，如免疫球蛋白和抗菌肽，有助于防止微生物粘附到肠道表面，抑制细菌代谢，中和毒素和病毒。”。

Building on these findings, PanTheryx commissioned an observational pilot study led by Harry Oken, M.D., an internist and Adjunct Professor of Medicine at the University of Maryland and former Chair of the Department of Medicine at Johns Hopkins Howard County Medical Center, and Michael Roizen, M.D., an internist, anesthesiologist and Chief Wellness Officer Emeritus at the Cleveland Clinic, to explore Relesium’s effectiveness among GLP-1 medication patients..

基于这些发现，PanTheryx委托马里兰大学医学博士哈里·奥肯（HarryOken）和医学博士迈克尔·罗岑（MichaelRoizen）进行了一项观察性试点研究，哈里·奥肯是马里兰大学的内科医生兼副教授，曾任约翰·霍普金斯霍华德县医学中心医学系主任，克利夫兰诊所（Cleveland Clinic）的内科医生、麻醉师兼首席健康官，以探索Relesium在GLP-1药物治疗患者中的有效性。。

“The rapid improvements observed with Relesium offer a natural remedy and show strong potential to help patients feel better, faster,” said Dr. Harry Oken, lead investigator of the observational pilot study. “By easing gastrointestinal distress and aiding gut health, Relesium enables patients to comfortably and safely take the prescribed dose of GLP-1s in order to achieve their maximum intended benefits.”.

该观察性试点研究的首席研究员哈里·奥肯博士说：“Relesium观察到的快速改善提供了一种天然的治疗方法，并显示出很大的潜力，可以帮助患者更快地感觉更好。”。“通过缓解胃肠道痛苦和帮助肠道健康，Relesium使患者能够舒适安全地服用规定剂量的GLP-1，以实现其最大的预期益处。”。

Eighteen participants using GLP-1 medications enrolled in the study, ten of which experienced gastrointestinal symptoms and were administered Relesium. Initial results are promising, showing that all ten reported notable improvement and reduction in gut-related symptoms after adding Relesium to their regimen.

18名使用GLP-1药物的参与者参加了这项研究，其中10名经历了胃肠道症状并服用了Relesium。最初的结果是有希望的，表明在他们的方案中加入Relesium后，所有十个都报告了肠道相关症状的显着改善和减少。

A placebo-controlled trial is planned to further validate Relesium’s efficacy..

计划进行一项安慰剂对照试验，以进一步验证Relesium的疗效。。

A Legacy of Innovation and Expertise

创新和专业知识的遗产

The launch of Relesium reflects the extensive experience of PanTheryx’s leadership and science teams, who collectively bring decades of knowledge in developing breakthrough health ingredients. Their achievements include the launch of life’sDHA®, a pioneering omega-3 ingredient from Martek Biosciences, now DSM-Firmenich, which became a half a billion dollar revenue brand and sought-after nutrition solution for global manufacturers such as Nestlé, Danone, General Mills, Abbott and Bristol Myers Squibb.

Relesium的推出反映了PanTheryx领导层和科学团队的丰富经验，他们共同带来了数十年来开发突破性健康成分的知识。他们的成就包括推出life'sDHA®，这是Martek Biosciences（现为DSM Firmenich）的一种开创性的ω-3成分，它成为了5亿美元的收入品牌，并成为雀巢（Nestlé）、达能（Danone）、通用磨坊（General Mills）、雅培（Abbott）和百时美施贵宝（Bristol-Myers Squibb）等全球制造商追求的营养解决方案。

With Relesium, the team once again delivers a patented, science-backed product for companies looking to support those taking GLP-1s..

通过Relesium，该团队再次为寻求支持服用GLP-1的公司提供了一种获得专利的科学支持产品。。

Relesium is launching in powder format, which can be used as a standalone supplement or within other product formulations starting January 2025. Additional formats and formulations are under development for future applications.

Relesium以粉末形式推出，从2025年1月开始，它可以作为独立的补充剂或在其他产品配方中使用。其他格式和配方正在开发中，以备将来应用。

To learn more about Relesium or PanTheryx, visit: www.pantheryx.com/relesium.

要了解有关Relesium或PanTheryx的更多信息，请访问：www.PanTheryx.com/Relesium。

About PanTheryx®

关于PanTheryx®

PanTheryx® is a premier science-based health and nutrition company dedicated to bringing category-leading products and solutions to the human health and wellness markets. From leading cutting-edge research to supplying best-in-class ingredients to commercializing category-leading consumer brands, PanTheryx is dedicated to delivering revolutionary digestive, immune, and microbiome health approaches.

PanTheryx®是一家以科学为基础的顶级健康和营养公司，致力于为人类健康和保健市场带来类别领先的产品和解决方案。从领先的尖端研究到提供一流的配料，再到商业化类别领先的消费品牌，PanTheryx致力于提供革命性的消化、免疫和微生物健康方法。

The PanTheryx global portfolio of consumer brands includes TruBiotics®, Life’s First Naturals®, and DiaResQ®. For more information, please visit www.pantheryx.com..

PanTheryx全球消费品牌组合包括TruBiotics®、Life's First Naturals®和DiaResQ®。欲了解更多信息，请访问www.pantheryx.com。。